The post Here’s Why Cardano Price Has Not Reclaimed $0.30 appeared on BitcoinEthereumNews.com. Cardano price remains under pressure as it struggles to break aboveThe post Here’s Why Cardano Price Has Not Reclaimed $0.30 appeared on BitcoinEthereumNews.com. Cardano price remains under pressure as it struggles to break above

Here’s Why Cardano Price Has Not Reclaimed $0.30

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Cardano price remains under pressure as it struggles to break above a descending trendline near $0.25. The ADA price trades around $0.25 after briefly testing the upper boundary of a downward channel. Earlier this week, the token rebounded toward $0.29 before slipping into consolidation near the $0.25 zone.

Crypto Sell-Off Intensifies After Weak U.S. Jobs Data

The broader cryptocurrency market dropped about 3.56% in 24 hours amid rising global economic concerns. Bitcoin price slipped more than 4% and hovered below the $70,000 mark during the widespread market retreat.

Ethereum also weakened and traded under $2,000 despite showing signs of recovery earlier in the week. The decline occurred after a poor United States jobs report that indicated the economy had lost 92,000 jobs in February.

The oil prices shot up to over 86%, and investors responded with caution as tensions continued to intensify in the Middle East.

These events caused a risk-off thesis that drove most digital assets down concurrently. Despite positive news on retail partnerships in Switzerland, Cardano followed the overall market trend.

The network has recently achieved payment integration in 137 SPAR supermarket locations, which has increased real-world utility.

ADA Derivatives Market Shows Cooling Trend With Falling Open Interest

The open interest of Cardano futures declined by 2% to $436 million on Thursday, continuing a consistent drop that started in mid-January.

The ongoing decline reflects dwindling trader participation in the entire derivatives markets and indicates the dwindling short-term confidence of investors. Trading volume decreased 24%, to $753.93 million daily.

In the meantime, blockchain statistics indicate that large holders sold about 230 million ADA tokens over the last week. That selling pressure, worth more than $63 million, has added further weight to ADA’s short term outlook. Technical indicators are still neutral, but further rejection around the trendline might keep Cardano in the falling range.

Cardano Price Outlook: ADA Risks Further Drop if $0.25 Support Fails

The ADA price plummeted to $0.2576 over the past 24-hours, extending weakness across the Cardano market.

The Cardano price was pushed by the sellers to the important $0.25 support after being rejected several times around the $0.30 resistance region.

The four-hour chart indicates that ADA trades within a sideways formation between the support at $0.25 and resistance at $0.30.

The RSI indicator is around 35, indicating a decreasing ability and approaching oversold. In the meanwhile, ADX is close to 11, which proves that the market does not have a strong directional trend as of now.

Once the support of $0.25 is broken decisively, ADA can move to the next down target at $0.23. However, a rebound from this zone may push the price back toward $0.27 and $0.28 resistance levels as per the full Cardano forecast report.

Source: ADA/USDT 4-hour chart: Tradingview

A stronger bullish recovery could open the path toward the major $0.30 resistance area.

Source: https://coingape.com/markets/heres-why-cardano-price-has-not-reclaimed-0-30/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09